Reid T. Powell

Sep 6, 2024 | biorxiv.org | Susmita Ghosh |Fan Fan |Reid T. Powell |Yong D. Park

AbstractBackground: KRAS is frequently mutated in the tumors of patients with metastatic colorectal cancer (mCRC) and thus represents a valid target for therapy. However, the strategies of targeting KRAS directly and targeting the downstream effector mitogen-activated protein kinase kinase (MEK) via monotherapies have shown limited efficacy. Thus, there is a strong need for novel, effective combination therapies to improve MEK-inhibitor efficacy in patients with KRAS-mutated mCRC.

Aug 28, 2024 | digitalcommons.library.tmc.edu | Fan Fan |Susmita Ghosh |Reid T. Powell |Jason Roszik

AbstractMetastatic colorectal cancer (mCRC) is the second leading cause of cancer deaths in the United States. More than 50% of patients with mCRC harbor mutations of the oncogenic driver RAS (KRAS or NRAS). Because directly targeting most mutations of RAS is technically challenging, researchers have concentrated on targeting MEK, a downstream mediator of RAS. However, targeting MEK as single-agent therapy is ineffective in patients with mCRC.

May 26, 2024 | nature.com | Reid T. Powell |Amanda Rinkenbaugh |Xiaomei Zhang |Yuan Qi |Clifford Stephan |Peter J Davies | +2 more

AbstractTriple negative breast cancer (TNBC) accounts for 15–20% of breast cancer cases in the United States. Systemic neoadjuvant chemotherapy (NACT), with or without immunotherapy, is the current standard of care for patients with early-stage TNBC. However, up to 70% of TNBC patients have significant residual disease once NACT is completed, which is associated with a high risk of developing recurrence within two to three years of surgical resection.